Gyre Therapeutics (GYRE) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Gyre Therapeutics (GYRE) is Neutral.

The composite score behind that read is -0.13, weighing +0.10 of bullish evidence against -0.26 bearish.

Gyre Therapeutics last closed at $7.35, +3.38% on the session.

Against the IVW growth benchmark the position is +2.46% over the forecast window.

The read is built from 12 underlying insights — 5 bullish and 7 bearish.

Agreement across those insights is 58%.

3 graded predictions for GYRE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Gyre Therapeutics in the 26th percentile on return on equity, where 100 is best.

Gyre Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $753.90M.

StockMap tracks Gyre Therapeutics as the 141st largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Gyre Therapeutics ranks 91st of 344 in the group, against a group median of -0.21.